Skip to main content

Want a detailed portfolio tracker?

ELVN
NASDAQ
$51.67

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its proprietary therapeutic platforms. With a robust pipeline of advanced drug candidates developed using cutting-edge biopharmaceutical technologies, the company is dedicated to enhancing patient care and quality of life. Enliven's commitment to scientific excellence and its mission to fulfill unmet needs in oncology strategically position it for substantial shareholder value while making a meaningful contribution to the healthcare ecosystem.
Website: https://www.enliventherapeutics.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Buy
Target: $66 (+27.73%)

Market Cap

$3.24B

Free Cash Flow Yield

-2.02%

Beta (5Y)

1.16

Price Chart

Valuation
Market Cap$3.24B
P/B8.15
Profitability
EBITDA-$116M
EPS-$1.65
Financial Health
Free Cash Flow Yield-2.02%
Growth & Risk
EPS 5Y CAGR-7.13%
FCF 5Y CAGR+11.85%
Beta (5Y)1.16
Sharpe Ratio1.30